Wedbush Weighs in on Biogen’s Q4 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) – Equities researchers at Wedbush lifted their Q4 2025 EPS estimates for Biogen in a research report issued to clients and investors on Friday, May 2nd. Wedbush analyst L. Chico now expects that the biotechnology company will earn $3.95 per share for the quarter, up from their previous estimate of $3.87. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen’s Q1 2026 earnings at $4.06 EPS, Q2 2026 earnings at $4.06 EPS, Q3 2026 earnings at $3.94 EPS, Q4 2026 earnings at $3.73 EPS, FY2027 earnings at $16.97 EPS, FY2028 earnings at $20.23 EPS and FY2029 earnings at $20.95 EPS.

Other analysts have also recently issued reports about the company. Canaccord Genuity Group dropped their price target on Biogen from $265.00 to $220.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Royal Bank of Canada reduced their price objective on shares of Biogen from $217.00 to $205.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Piper Sandler dropped their target price on shares of Biogen from $135.00 to $115.00 and set a “neutral” rating for the company in a report on Tuesday, April 29th. Truist Financial dropped their target price on Biogen from $210.00 to $199.00 and set a “buy” rating for the company in a research report on Tuesday, April 29th. Finally, Scotiabank cut their target price on Biogen from $244.00 to $224.00 and set a “sector outperform” rating on the stock in a report on Thursday, February 13th. Twenty equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $192.70.

Biogen Price Performance

Shares of BIIB opened at $116.92 on Monday. The firm has a market capitalization of $17.11 billion, a PE ratio of 10.45, a PEG ratio of 1.51 and a beta of 0.13. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $238.00. The company’s 50-day moving average is $129.75 and its 200-day moving average is $145.77.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported $3.02 EPS for the quarter, missing the consensus estimate of $3.26 by ($0.24). Biogen had a net margin of 16.87% and a return on equity of 14.98%. The company had revenue of $2.43 billion during the quarter, compared to analyst estimates of $2.25 billion. During the same period in the previous year, the company posted $3.67 EPS. The company’s quarterly revenue was up 6.2% compared to the same quarter last year.

Insider Activity

In related news, Director Stephen A. Sherwin sold 8,760 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the sale, the director now owns 11,318 shares in the company, valued at approximately $1,697,926.36. This trade represents a 43.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by corporate insiders.

Institutional Trading of Biogen

Large investors have recently bought and sold shares of the company. Larson Financial Group LLC grew its position in shares of Biogen by 640.9% in the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 141 shares in the last quarter. Lee Danner & Bass Inc. purchased a new stake in Biogen in the 4th quarter worth approximately $25,000. Opal Wealth Advisors LLC purchased a new position in Biogen during the first quarter worth about $26,000. Colonial Trust Co SC increased its stake in Biogen by 9,300.0% in the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 186 shares during the last quarter. Finally, Private Trust Co. NA lifted its position in Biogen by 74.8% during the first quarter. Private Trust Co. NA now owns 229 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 98 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.